Compare Stocks

Date Range: 

 CASI PharmaceuticalsEiger BioPharmaceuticalsAutolus TherapeuticsCabaletta BioProtalix BioTherapeutics
SymbolNASDAQ:CASINASDAQ:EIGRNASDAQ:AUTLNASDAQ:CABANYSEAMERICAN:PLX
Price Information
Current Price$1.43$8.34$4.99$9.39$2.94
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.81.31.61.3
Analysis Score3.53.53.43.53.5
Community Score2.52.92.42.62.4
Dividend Score0.00.00.00.00.0
Ownership Score1.72.50.01.70.0
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$4.40$25.50$21.00$21.00$7.00
% Upside from Price Target207.69% upside205.76% upside320.84% upside123.64% upside138.10% upside
Trade Information
Market Cap$199.91 million$283.15 million$261.21 million$234.07 million$133.43 million
Beta0.411.541.751.672.87
Average Volume1,454,376251,755750,219110,2131,237,761
Sales & Book Value
Annual Revenue$4.13 millionN/A$2.91 millionN/A$54.69 million
Price / Sales48.40N/A89.76N/A2.44
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.76 per share$2.31 per share$5.67 per share$5.76 per share($4.74) per share
Price / Book1.88N/A0.88N/A-0.62
Profitability
Net Income$-46,030,000.00$-70,250,000.00$-123,850,000.00$-16,940,000.00$-18,280,000.00
EPS($0.42)($3.08)($2.88)($4.07)($1.23)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A294.00
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-402.87%N/A-8,652.90%N/A-10.84%
Return on Equity (ROE)-60.96%-100.60%-54.01%-22.99%N/A
Return on Assets (ROA)-42.48%-57.76%-44.19%-22.38%-9.74%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.27%N/AN/AN/A
Current Ratio14.99%6.23%7.43%27.95%1.37%
Quick Ratio14.86%6.23%7.43%27.95%1.07%
Ownership Information
Institutional Ownership Percentage31.95%68.77%22.86%68.00%14.28%
Insider Ownership Percentage24.75%5.80%N/A6.51%1.64%
Miscellaneous
Employees1442837633207
Shares Outstanding139.80 million33.95 million52.35 million24.93 million45.38 million
Next Earnings DateN/A8/5/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)5/14/2021 (Confirmed)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Protalix BioTherapeutics (PLX) Scheduled to Post Quarterly Earnings on FridayProtalix BioTherapeutics (PLX) Scheduled to Post Quarterly Earnings on Friday
americanbankingnews.com - May 11 at 9:00 AM
HC Wainwright Trims Protalix BioTherapeutics (NYSEAMERICAN:PLX) Target Price to $7.00HC Wainwright Trims Protalix BioTherapeutics (NYSEAMERICAN:PLX) Target Price to $7.00
americanbankingnews.com - May 10 at 9:06 AM
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
finance.yahoo.com - May 7 at 12:00 PM
Protalix BioTherapeutics Inc. (NYSE:PLX) Down Almost -38.85% in 1 Month, But Long Term Looking GoodProtalix BioTherapeutics Inc. (NYSE:PLX) Down Almost -38.85% in 1 Month, But Long Term Looking Good
marketingsentinel.com - May 7 at 7:58 AM
Will current price volatility hamper Protalix BioTherapeutics Inc. (PLX) future potential?Will current price volatility hamper Protalix BioTherapeutics Inc. (PLX) future potential?
marketingsentinel.com - May 4 at 12:24 PM
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Price Target Cut to $7.00 by Analysts at HC WainwrightProtalix BioTherapeutics (NYSEAMERICAN:PLX) Price Target Cut to $7.00 by Analysts at HC Wainwright
americanbankingnews.com - May 3 at 8:10 AM
Analysts Expect Breakeven For Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Before LongAnalysts Expect Breakeven For Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Before Long
nasdaq.com - May 1 at 1:24 PM
Protalix BioTherapeutics, Inc. (NYSE:PLX) Stock Dropped -24.68% Over A Month – Is There Any Hope Of A Gain?Protalix BioTherapeutics, Inc. (NYSE:PLX) Stock Dropped -24.68% Over A Month – Is There Any Hope Of A Gain?
marketingsentinel.com - April 30 at 9:58 AM
Protalix BioTherapeutics Inc. [PLX] moved down -32.59: Why It’s ImportantProtalix BioTherapeutics Inc. [PLX] moved down -32.59: Why It’s Important
dbtnews.com - April 29 at 10:36 PM
PLX: Pandemic Backup Impedes FDA Site SurveyPLX: Pandemic Backup Impedes FDA Site Survey
finance.yahoo.com - April 29 at 10:29 AM
Protalix shares crumble on CRL for Fabry disease therapyProtalix shares crumble on CRL for Fabry disease therapy
bioworld.com - April 29 at 7:34 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) Investigation
finance.yahoo.com - April 28 at 5:59 PM
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDAProtalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
finance.yahoo.com - April 28 at 3:20 PM
Why Protalix BioTherapeutics Stock Is Plunging TodayWhy Protalix BioTherapeutics Stock Is Plunging Today
finance.yahoo.com - April 28 at 3:20 PM
PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% TodayPLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today
feedproxy.google.com - April 28 at 9:13 AM
BRIEF-Protalix Biotherapeutics Says Co And Chiesi Global Rare Diseases Receive Complete Response Letter For Pegunigalsidase Alfa From FDABRIEF-Protalix Biotherapeutics Says Co And Chiesi Global Rare Diseases Receive Complete Response Letter For Pegunigalsidase Alfa From FDA
msn.com - April 28 at 8:28 AM
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes ShoppingThe Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
msn.com - April 28 at 8:28 AM
Protalix Receives Complete Response Letter Regarding BLA For PRX-102 - Quick FactsProtalix Receives Complete Response Letter Regarding BLA For PRX-102 - Quick Facts
nasdaq.com - April 28 at 7:58 AM
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDAProtalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
prnewswire.com - April 28 at 3:04 AM
Protalix BioTherapeutics, Inc. (NYSE:PLX)’s Stock Price Continues to FallProtalix BioTherapeutics, Inc. (NYSE:PLX)’s Stock Price Continues to Fall
stocksregister.com - April 26 at 12:54 PM
The Future Of Protalix BioTherapeutics, Inc. (NYSE:PLX) In 2021The Future Of Protalix BioTherapeutics, Inc. (NYSE:PLX) In 2021
stocksregister.com - April 22 at 5:55 PM
Stock Traders Purchase High Volume of Protalix BioTherapeutics Put Options (NYSEAMERICAN:PLX)Stock Traders Purchase High Volume of Protalix BioTherapeutics Put Options (NYSEAMERICAN:PLX)
americanbankingnews.com - April 22 at 6:56 AM
Protalix BioTherapeutics Target of Unusually High Options Trading (NYSEAMERICAN:PLX)Protalix BioTherapeutics Target of Unusually High Options Trading (NYSEAMERICAN:PLX)
americanbankingnews.com - April 21 at 11:20 AM
Protalix BioTherapeutics, Inc. (NYSE:PLX) Stock Forecast for 2021: Bullish Signs Point to $15 per ShareProtalix BioTherapeutics, Inc. (NYSE:PLX) Stock Forecast for 2021: Bullish Signs Point to $15 per Share
marketingsentinel.com - April 20 at 1:55 PM
Protalix BioTherapeutics, Inc.: Making Heads or Tails of PLX StockProtalix BioTherapeutics, Inc.: Making Heads or Tails of PLX Stock
stocksregister.com - April 19 at 1:03 PM
DateCompanyBrokerageAction
5/3/2021CASI PharmaceuticalsMizuhoInitiated Coverage
11/10/2020CASI PharmaceuticalsOppenheimerReiterated Rating
3/24/2020CASI PharmaceuticalsHC WainwrightReiterated Rating
5/11/2021Eiger BioPharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
1/19/2021Eiger BioPharmaceuticalsWedbushReiterated Rating
9/29/2020Eiger BioPharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
12/16/2019Eiger BioPharmaceuticalsGilford SecuritiesInitiated Coverage
6/26/2019Eiger BioPharmaceuticalsKeyCorpInitiated Coverage
1/28/2019Eiger BioPharmaceuticalsRobert W. BairdInitiated Coverage
12/19/2018Eiger BioPharmaceuticalsBTIG ResearchBoost Price Target
5/6/2021Autolus TherapeuticsNeedham & Company LLCLower Price Target
3/16/2021Autolus TherapeuticsRedburn PartnersReiterated Rating
1/29/2021Autolus TherapeuticsJPMorgan Chase & Co.Downgrade
1/7/2021Autolus TherapeuticsTruistLower Price Target
9/23/2020Autolus TherapeuticsWilliam BlairReiterated Rating
7/22/2020Autolus TherapeuticsSunTrust BanksInitiated Coverage
6/17/2020Autolus TherapeuticsJefferies Financial GroupReiterated Rating
1/8/2021Cabaletta BioChardan CapitalReiterated Rating
7/15/2020Cabaletta BioMorgan StanleyBoost Price Target
11/27/2019Cabaletta BioEvercore ISIInitiated Coverage
11/19/2019Cabaletta BioCowenInitiated Coverage
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.